Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: Too high dose infused at labour?

6Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

AIMS The main goal of the study was to describe the pharmacokinetics of maternal zidovudine (ZDV) administration during pregnancy and labour and to evaluate their impact on fetal concentrations and exposures. METHODS A total of 195 HIV-infected pregnant and non-pregnant women aged 16-59 years were included and 273 maternal and 79 cord blood ZDV concentrations were collected. A population pharmacokinetic model was developed to describe ZDV concentrations as a function of time in the mother and the fetus. Fetal exposures resulting from maternal oral administration and infusion were estimated and compared with therapeutic exposures (3-5 mg l-1 h) and to exposure providing higher risk of toxicity (>8.4 mg l-1 h). Different protocols for ZDV administration during labour were simulated. RESULTS The median fetal exposure and the percentage of children with values above 8.4 mg l-1 h were 3.20 mg l-1 h and 0% after maternal oral administration, respectively, and 9.71 mg l-1 h and 51% after maternal infusion during labour. Two options were considered to reduce fetal exposure during labour: (i) maternal infusion rates could be 1mg kg-1 h-1 during 1 h followed by 0.5 mg kg-1 h-1 and (ii) the mother could only take oral ZDV every 5 h from start of labour until delivery with her neonate having their first ZDV dose as soon as possible after birth. CONCLUSIONS Zidovudine exposures are very important during labour and during the first days of a neonate's life. Maternal ZDV dose should be reduced in addition to the neonate doses reduction already proposed. © 2014 The British Pharmacological Society.

References Powered by Scopus

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment

3458Citations
N/AReaders
Get full text

Likelihood based approaches to handling data below the quantification limit using NONMEM VI

278Citations
N/AReaders
Get full text

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

180Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models

52Citations
N/AReaders
Get full text

Pharmacokinetics, placental and breast milk transfer of antiretroviral drugs in pregnant and lactating women living with HIV

19Citations
N/AReaders
Get full text

Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fauchet, F., Treluyer, J. M., Valade, E., Benaboud, S., Pannier, E., Firtion, G., … Hirt, D. (2014). Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: Too high dose infused at labour? British Journal of Clinical Pharmacology, 78(6), 1387–1396. https://doi.org/10.1111/bcp.12459

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

80%

Researcher 2

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

60%

Pharmacology, Toxicology and Pharmaceut... 3

20%

Nursing and Health Professions 2

13%

Environmental Science 1

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free